PRLD

+ Watchlist + Portfolio

Prelude Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.78
52-Week Range: $0.98 – $6.65
Market Cap: $518.72M
P/E (TTM): —
EPS (TTM): -0.73
Dividend Yield: —

Advanced Metrics

Price/Book: 5.00
PEG Ratio: —
Return on Equity: -57.73%
Return on Assets: -27.15%
Gross Margin: 100.00%
Operating Margin: -270.93%
Profit Margin: -269.75%
Current Ratio: 4.07
Debt/Equity: 0.13
Total Debt: $17.65M
Free Cash Flow: $-13.84M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $461.20M

PRLD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$7.00M	$12.14M
Research & Development	$92.89M	$103.39M	$118.00M	$94.30M
Selling, General & Admin	$30.65M	$28.88M	$28.72M	$22.41M
Operating Expenses	$123.54M	$132.28M	$146.71M	$116.71M
Operating Income	-$123.54M	-$132.28M	-$139.71M	-$104.57M
EBITDA	-$122.22M	-$131.11M	-$137.94M	-$102.86M
Pretax Income	-$115.44M	-$121.83M	-$127.17M	-$99.50M
Net Income	-$115.44M	-$121.83M	-$127.17M	-$99.50M
Diluted EPS	-2.44	-2.02	-1.68	-1.29
Diluted Shares	47.37M	60.36M	75.81M	76.96M

PRLD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$30.61M	$25.29M	$12.47M	$35.26M
Current Assets	$204.38M	$235.59M	$135.90M	$105.69M
Total Assets	$220.50M	$277.67M	$175.51M	$141.31M
Current Liabilities	$21.70M	$21.83M	$25.64M	$52.99M
Total Debt	$1.83M	$16.89M	$18.02M	$17.79M
Total Liabilities	$25.06M	$40.58M	$44.06M	$72.68M
Retained Earnings	-$334.56M	-$456.39M	-$583.56M	-$683.06M
Shareholders' Equity	$195.44M	$237.09M	$131.46M	$68.64M
Working Capital	$182.68M	$213.76M	$110.25M	$52.70M

PRLD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$83.73M	-$107.06M	-$102.89M	-$56.30M
Capital Expenditure	-$3.02M	-$3.51M	-$764.00K	-$67.00K
Free Cash Flow	-$86.75M	-$110.58M	-$103.65M	-$56.37M
Depreciation & Amortisation	$1.32M	$1.17M	$1.77M	$1.71M
Stock-Based Compensation	$25.14M	$25.62M	$21.34M	$11.91M
Investing Cash Flow	$81.69M	-$34.65M	$90.19M	$53.46M
Financing Cash Flow	$815.00K	$136.40M	-$120.00K	$24.82M
Net Change in Cash	-$1.22M	-$5.31M	-$12.82M	$21.97M

PRLD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$6.50M	$5.64M	$4.58M
Research & Development	$28.82M	$25.78M	$21.71M	$17.99M	$13.60M
Selling, General & Admin	$5.79M	$6.41M	$5.21M	$5.00M	$5.16M
Operating Expenses	$34.61M	$32.19M	$26.92M	$22.99M	$18.76M
Operating Income	-$34.61M	-$32.19M	-$20.42M	-$17.35M	-$14.18M
EBITDA	-$34.17M	-$31.76M	-$19.99M	-$16.93M	-$13.79M
Pretax Income	-$32.09M	-$31.23M	-$19.73M	-$16.46M	-$10.38M
Net Income	-$32.09M	-$31.23M	-$19.73M	-$16.46M	-$10.38M
Diluted EPS	-0.42	-0.41	-0.26	—	-0.13
Diluted Shares	75.99M	75.99M	76.13M	—	82.52M

PRLD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$40.27M	$25.75M	$47.53M	$35.26M	$21.76M
Current Assets	$102.40M	$76.88M	$58.33M	$105.69M	$84.59M
Total Assets	$141.26M	$114.92M	$94.75M	$141.31M	$119.64M
Current Liabilities	$19.79M	$20.91M	$18.19M	$52.99M	$41.72M
Total Debt	$17.92M	$17.92M	$17.85M	$17.79M	$17.72M
Total Liabilities	$38.08M	$39.08M	$36.22M	$72.68M	$59.46M
Retained Earnings	-$615.65M	-$646.88M	-$666.60M	-$683.06M	-$693.45M
Shareholders' Equity	$103.18M	$75.84M	$58.53M	$68.64M	$60.18M
Working Capital	$82.62M	$55.97M	$40.14M	$52.70M	$42.87M

PRLD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$34.23M	-$26.07M	-$19.11M	$23.12M	-$21.68M
Capital Expenditure	-$47.00K	-$20.00K	—	—	—
Free Cash Flow	-$34.28M	-$26.09M	-$19.11M	$23.12M	-$21.68M
Depreciation & Amortisation	$435.00K	$433.00K	$425.00K	$418.00K	$391.00K
Stock-Based Compensation	$3.83M	$3.81M	$2.42M	$1.84M	$2.00M
Investing Cash Flow	$62.19M	$11.52M	$40.09M	-$60.34M	$8.50M
Financing Cash Flow	-$160.00K	$37.00K	-$5.00K	$24.94M	-$314.00K
Net Change in Cash	$27.80M	-$14.52M	$20.97M	-$12.28M	-$13.50M

Market Snapshot

About

Prelude Therapeutics Incorporated operates as a clinical-stage precision oncology company developing targeted cancer therapies. Headquartered in Wilmington, Delaware, the company focuses on discovering and creating small molecule therapies designed to target key drivers of cancer cell growth and resistance mechanisms. Prelude's pipeline centers on precision medicines for genomically defined cancers, with lead programs targeting CDK4/6, SMARCA2/4, and other critical pathways in tumor biology.

The company's most advanced candidates include PRT3789, a SMARCA2-selective degrader in Phase 1 clinical trials for SMARCA4-mutant cancers, and PRT2527, a CDK9 inhibitor for MYC-altered solid tumors and blood cancers. Prelude also develops PRT1419, targeting the Cereblon pathway in hematologic malignancies. The company employs approximately 100 people and maintains research operations focused on structure-based drug design and medicinal chemistry.

In December 2024, Prelude announced a strategic review process to explore alternatives for maximizing shareholder value, including potential mergers, asset sales, or other strategic transactions. The company collaborates with academic institutions and maintains partnerships to advance its precision medicine platform. Founded in 2016, Prelude went public in 2020 and trades on NASDAQ under the ticker PRLD. The company continues to enroll patients in multiple clinical trials while managing its cash resources to fund ongoing development programs.